Join MySLAS Social


Call for Papers - Assay Guidance Manual for Drug Discovery: Robust or Go Bust

Proposals accepted until October 1, 2020!

Submit Proposals Here

SLAS Discovery Guest Editors Sarine Markossian, Ph.D., Matthew D Hall, Ph.D., G. Sitta Sittampalam, Ph.D., Jayme Dahlin, M.D., Ph.D. and Nathan P. Coussens, Ph.D. invite the submission of abstracts for the Assay Guidance Manual for Drug Discovery: Robust or Go Bust for publication in a 2021 Special Issue. The abstracts will be used to select and invite papers for review and publication consideration.

The Guest Editors seek high-quality, short- or full-length research reports, reviews and perspectives related to the Assay Guidance Workshop for High-Throughput Screening and Lead Discovery. It is recommended that submissions contain specific novel examples and/or new case studies that will reinforce best practices in assay development exemplified by the Assay Guidance Manual (AGM).

  • Development, optimization and implementation of in vitro biochemical, biophysical and cell-based assays
    • Statistical design of experiments for assay development
    • Concepts, guidelines and best-practices for robust biochemical and cell-based assays
    • Biophysical methods for small molecule discovery and validation
    • Kinetics of target binding: kinetic artifacts in potency assays and methods for measuring binding kinetics
    • The application of stem cells in drug discovery
    • Predictive strategies for drug-induced liver injury (DILI)
  • High-Content Assays
    • Assay development for high-content screening and best practices
    • Approaches for multi-parametric phenotypic high-throughput screening
    • Data analysis for high-content screening
    • Artificial intelligence (AI) and machine learning (ML) in high-content screening
  • Assays for lead optimization
    • Lead selection and optimization by medicinal chemistry
    • Survey of assay technologies for HTS and lead optimization
    • Mass spectrometry for drug screening and lead optimization
    • Biophysical methods for lead optimization
  • Assays and concepts to identify and mitigate sources of artifacts and interferences
    • Common bioassay interference mechanisms including aggregation and chemical reactivity
    • Strategies to design small molecule discovery assays and counter screens to enrich hits with genuine biological activity
    • Common sources of assay artifacts from instrumentation
    • Optimal selection of instrumentation, reagents and assay technologies to reduce assay interferences
  • Assay validation, operations, quality control and data analysis
    • Assay operations: planning for robust assays
    • Microplate selection and recommended practices in high-throughput screening and quantitative biology
    • Basic assay statistics, data analysis and rules of thumb
    • Reproducibility, comparison and correlation of in vitro assays
    • Reproducibility and differentiability in potency assays
    • Best practices in compound management
  • Pharmacokinetics and drug metabolism
    • In vitro assessment of ADME properties of lead compounds
    • ADME assay optimization
  • Use of complex in vitro models (CIVMs) in preclinical drug discovery
    • The emergence of CIVMs in disease modeling
    • The emergence of CIVMs in safety testing

Submit your manuscript proposal before October 1, 2020. Submissions should include your name, contact information, affiliation, a working title and abstract (250-500 words) as an MS Word document.

Invited manuscripts will need to be completed and submitted by February 1, 2021. All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Discovery Special Issue.

Publication note: After submissions are accepted, they typically publish online ahead-of-print within 30 days and become immediately searchable and citable with a DOI.

Questions? Please e-mail or call +1.630.256.7527, ext. 106.